Stevanato Group Achieves 8% Revenue Growth and Expands Margins in Q2 2025
ByAinvest
Thursday, Aug 7, 2025 2:57 am ET1min read
STVN--
Stevanato Group reported Q2 2025 revenue of €280.0 million, an 8% increase YoY, driven by a 10% rise in its Biopharmaceutical and Diagnostic Solutions segment. High-value solutions made up 42% of total revenue, with gross profit margin increasing 210 basis points to 28.1%. The company maintains its FY2025 guidance, expecting revenue of €1.160 billion to €1.190 billion and adjusted EBITDA of €288.5 million to €301.8 million.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet